These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20233033)

  • 1. Assessment of in silico models for fraction of unbound drug in human liver microsomes.
    Gao H; Steyn SJ; Chang G; Lin J
    Expert Opin Drug Metab Toxicol; 2010 May; 6(5):533-42. PubMed ID: 20233033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct determination of the ratio of unbound fraction in plasma to unbound fraction in microsomal system (fu p/fu mic) for refined prediction of phase I mediated metabolic hepatic clearance.
    Deshmukh SV; Harsch A
    J Pharmacol Toxicol Methods; 2011; 63(1):35-9. PubMed ID: 20433934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data.
    Kilford PJ; Gertz M; Houston JB; Galetin A
    Drug Metab Dispos; 2008 Jul; 36(7):1194-7. PubMed ID: 18411401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based prediction of the nonspecific binding of drugs to hepatic microsomes.
    Li H; Sun J; Sui X; Yan Z; Sun Y; Liu X; Wang Y; He Z
    AAPS J; 2009 Jun; 11(2):364-70. PubMed ID: 19440845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microsome composition-based model as a mechanistic tool to predict nonspecific binding of drugs in liver microsomes.
    Poulin P; Haddad S
    J Pharm Sci; 2011 Oct; 100(10):4501-17. PubMed ID: 21574165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol.
    Obach RS
    Drug Metab Dispos; 1997 Dec; 25(12):1359-69. PubMed ID: 9394025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of intrinsic clearance for prediction of human hepatic clearance.
    Chao P; Uss AS; Cheng KC
    Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):189-98. PubMed ID: 20073997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Fraction Unbound in Microsomal and Hepatocyte Incubations: A Comparison of Methods across Industry Datasets.
    Winiwarter S; Chang G; Desai P; Menzel K; Faller B; Arimoto R; Keefer C; Broccatell F
    Mol Pharm; 2019 Sep; 16(9):4077-4085. PubMed ID: 31348668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prediction of human clearance from hepatic microsomal metabolism data.
    Obach RS
    Curr Opin Drug Discov Devel; 2001 Jan; 4(1):36-44. PubMed ID: 11727321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico modeling of nonspecific binding to human liver microsomes.
    Gao H; Yao L; Mathieu HW; Zhang Y; Maurer TS; Troutman MD; Scott DO; Ruggeri RB; Lin J
    Drug Metab Dispos; 2008 Oct; 36(10):2130-5. PubMed ID: 18606744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-Human Predictions of Hepatic Clearance for Drugs With the Well-Stirred Model: Comparative Assessment Between Models of Fraction Unbound Based Either on the Free Drug Hypothesis, Albumin-Facilitated Hepatic Uptake or Dynamic Binding Kinetics.
    Poulin P
    J Pharm Sci; 2024 Aug; 113(8):2641-2650. PubMed ID: 38796154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct determination of unbound intrinsic drug clearance in the microsomal stability assay.
    Giuliano C; Jairaj M; Zafiu CM; Laufer R
    Drug Metab Dispos; 2005 Sep; 33(9):1319-24. PubMed ID: 15951446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of human pharmacokinetics--evaluation of methods for prediction of hepatic metabolic clearance.
    Fagerholm U
    J Pharm Pharmacol; 2007 Jun; 59(6):803-28. PubMed ID: 17637173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of hepatic microsomal intrinsic clearance and human clearance values for drugs.
    Nikolic K; Agababa D
    J Mol Graph Model; 2009 Oct; 28(3):245-52. PubMed ID: 19713138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of human pharmacokinetics--improving microsome-based predictions of hepatic metabolic clearance.
    Fagerholm U
    J Pharm Pharmacol; 2007 Oct; 59(10):1427-31. PubMed ID: 17910819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes.
    Riley RJ; McGinnity DF; Austin RP
    Drug Metab Dispos; 2005 Sep; 33(9):1304-11. PubMed ID: 15932954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of in silico models for human liver microsomal stability.
    Lee PH; Cucurull-Sanchez L; Lu J; Du YJ
    J Comput Aided Mol Des; 2007 Dec; 21(12):665-73. PubMed ID: 17599241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations.
    Gertz M; Kilford PJ; Houston JB; Galetin A
    Drug Metab Dispos; 2008 Mar; 36(3):535-42. PubMed ID: 18096674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of hepatic clearance prediction using in vitro data: emphasis on fraction unbound in plasma and drug ionisation using a database of 107 drugs.
    Hallifax D; Houston JB
    J Pharm Sci; 2012 Aug; 101(8):2645-52. PubMed ID: 22700322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.
    Obach RS
    Drug Metab Dispos; 1999 Nov; 27(11):1350-9. PubMed ID: 10534321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.